JP2007515422A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007515422A5 JP2007515422A5 JP2006545506A JP2006545506A JP2007515422A5 JP 2007515422 A5 JP2007515422 A5 JP 2007515422A5 JP 2006545506 A JP2006545506 A JP 2006545506A JP 2006545506 A JP2006545506 A JP 2006545506A JP 2007515422 A5 JP2007515422 A5 JP 2007515422A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- pharmacologically active
- active derivative
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 29
- 239000003795 chemical substances by application Substances 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 16
- LZENMJMJWQSSNJ-UHFFFAOYSA-N 3H-1,2-dithiole-3-thione Chemical compound S=C1C=CSS1 LZENMJMJWQSSNJ-UHFFFAOYSA-N 0.000 claims 12
- 150000002540 isothiocyanates Chemical class 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 9
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 8
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 8
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims 8
- 229930003935 flavonoid Natural products 0.000 claims 8
- 235000017173 flavonoids Nutrition 0.000 claims 8
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 claims 8
- 150000002215 flavonoids Chemical class 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 239000013078 crystal Substances 0.000 claims 6
- 235000006539 genistein Nutrition 0.000 claims 6
- 229940045109 genistein Drugs 0.000 claims 6
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims 6
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims 5
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims 5
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims 5
- 238000002347 injection Methods 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- 230000005937 nuclear translocation Effects 0.000 claims 5
- 230000002207 retinal effect Effects 0.000 claims 5
- 230000004936 stimulating effect Effects 0.000 claims 5
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 claims 4
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims 4
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 claims 4
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 4
- 239000004258 Ethoxyquin Substances 0.000 claims 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims 4
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 claims 4
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 4
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 4
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 4
- 230000003111 delayed effect Effects 0.000 claims 4
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 claims 4
- 235000019285 ethoxyquin Nutrition 0.000 claims 4
- 229940093500 ethoxyquin Drugs 0.000 claims 4
- 238000002513 implantation Methods 0.000 claims 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims 4
- CKNAQFVBEHDJQV-UHFFFAOYSA-N oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 claims 4
- 229950008687 oltipraz Drugs 0.000 claims 4
- 230000036542 oxidative stress Effects 0.000 claims 4
- 235000005875 quercetin Nutrition 0.000 claims 4
- 229960001285 quercetin Drugs 0.000 claims 4
- 229960005559 sulforaphane Drugs 0.000 claims 4
- 235000015487 sulforaphane Nutrition 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 230000000699 topical effect Effects 0.000 claims 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 2
- 238000006845 Michael addition reaction Methods 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000002889 endothelial cell Anatomy 0.000 claims 2
- -1 genistein flavonoids Chemical class 0.000 claims 2
- 210000004498 neuroglial cell Anatomy 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- 230000001590 oxidative effect Effects 0.000 claims 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 claims 2
- 210000003668 pericyte Anatomy 0.000 claims 2
- 230000004797 therapeutic response Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53181103P | 2003-12-22 | 2003-12-22 | |
| PCT/US2004/042562 WO2005063249A1 (en) | 2003-12-22 | 2004-12-17 | Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007515422A JP2007515422A (ja) | 2007-06-14 |
| JP2007515422A5 true JP2007515422A5 (enExample) | 2007-10-18 |
Family
ID=34738705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006545506A Pending JP2007515422A (ja) | 2003-12-22 | 2004-12-17 | 糖尿病性網膜症および黄斑変性における結晶腔形成の処置のための薬剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20050137147A1 (enExample) |
| EP (1) | EP1696926A1 (enExample) |
| JP (1) | JP2007515422A (enExample) |
| AU (1) | AU2004308911B2 (enExample) |
| BR (1) | BRPI0417996A (enExample) |
| CA (1) | CA2548146A1 (enExample) |
| MX (1) | MXPA06006862A (enExample) |
| WO (1) | WO2005063249A1 (enExample) |
| ZA (1) | ZA200605378B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200604862B (en) * | 2003-12-22 | 2007-10-31 | Alcon Inc | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
| WO2005102345A1 (en) * | 2004-03-30 | 2005-11-03 | Alcon, Inc. | Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
| WO2006030907A1 (ja) * | 2004-09-16 | 2006-03-23 | Redox Bioscience Inc. | 網膜保護剤 |
| AU2006265113A1 (en) * | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| FR2902326B1 (fr) * | 2006-06-20 | 2008-12-05 | Oreal | Utilisation de la coumarine, de butylated hydroxyanisole et d'ethoxyquine pour le traitement de la canitie |
| WO2008016095A1 (en) * | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT |
| JP2008247898A (ja) * | 2007-03-08 | 2008-10-16 | Santen Pharmaceut Co Ltd | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| US20090324740A1 (en) * | 2008-06-13 | 2009-12-31 | Albritton Iv Ford D | Novel nasal spray |
| US20110250184A1 (en) * | 2008-12-16 | 2011-10-13 | Onconova Therapeutics ,Inc. | Methods for determining efficacy of a therapeutic regimen against deleterious effects of cytotoxic agents in human |
| WO2012009171A2 (en) * | 2010-07-15 | 2012-01-19 | The Schepens Eye Research Institute, Inc. | Compositions and methods of treatment of corneal endothelium disorders |
| EP2991621B1 (en) * | 2013-05-02 | 2020-12-09 | Retina Foundation of the Southwest | Two-layer ocular implant |
| EP3919052A4 (en) * | 2019-01-09 | 2022-10-05 | Fuso Pharmaceutical Industries, Ltd. | Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases |
| CN112716938A (zh) * | 2021-02-25 | 2021-04-30 | 新疆医科大学 | 鞣花酸在制备缓解眼组织病变的药物中的用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456757A (en) * | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
| US4678783B1 (en) * | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
| US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| US5124154A (en) * | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
| JP3193301B2 (ja) * | 1995-09-14 | 2001-07-30 | 麒麟麦酒株式会社 | 生理活性タンパク質ｐ１６０ |
| US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
| US5681854A (en) * | 1995-11-22 | 1997-10-28 | Alcon Laboratories, Inc. | Use of aliphatic carboxylic acid derivatives in ophthalmic disorders |
| US6271224B1 (en) * | 1995-12-21 | 2001-08-07 | Alcon Laboratories, Inc. | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia |
| WO1997028130A1 (en) * | 1996-02-02 | 1997-08-07 | Nippon Shinyaku Co., Ltd. | Isoquinoline derivatives and drugs |
| US6586425B2 (en) * | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
| ES2286834T5 (es) * | 1996-08-12 | 2011-01-31 | Mitsubishi Tanabe Pharma Corporation | Medicamentos que comprenden un inhibidor de la rho quinasa. |
| US5759787A (en) * | 1996-08-26 | 1998-06-02 | Tularik Inc. | Kinase assay |
| US6573044B1 (en) * | 1997-08-07 | 2003-06-03 | The Regents Of The University Of California | Methods of using chemical libraries to search for new kinase inhibitors |
| US6441033B1 (en) * | 1997-12-22 | 2002-08-27 | Alcon Manufacturing, Ltd. | 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists |
| US5958946A (en) * | 1998-01-20 | 1999-09-28 | Styczynski; Peter | Modulation of hair growth |
| US6274338B1 (en) * | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| US20010041174A1 (en) * | 1998-11-24 | 2001-11-15 | Najam Sharif | Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases |
| US6020383A (en) * | 1999-01-11 | 2000-02-01 | Eastman Chemicals Company | Method for reducing blood cholesterol and/or blood triglycerides |
| US7261881B1 (en) * | 1999-05-20 | 2007-08-28 | Yale University | Modulation of angiogenesis and wound healing |
| US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
| US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
| WO2002002190A2 (en) * | 2000-07-05 | 2002-01-10 | Johns Hopkins School Of Medicine | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
| GB0030727D0 (en) * | 2000-12-15 | 2001-01-31 | Lumitech Uk Ltd | Methods and kits for detecting kinase activity |
| US6756063B2 (en) * | 2001-03-29 | 2004-06-29 | Zoltan Laboratories, Llc | Methods and compositions for the treatment of human and animal cancers |
| US6884816B2 (en) * | 2001-08-31 | 2005-04-26 | Alcon, Inc. | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma |
| TWI335221B (en) * | 2001-09-27 | 2011-01-01 | Alcon Inc | Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| US7199122B2 (en) * | 2001-10-02 | 2007-04-03 | Fox Chase Cancer Center | Methods for inhibiting angiogenesis |
| WO2003033662A2 (en) * | 2001-10-16 | 2003-04-24 | Atherogenics, Inc. | Protection against oxidative stress and inflammation by a cytoprotective response element |
| ATE445405T1 (de) * | 2001-12-18 | 2009-10-15 | Brassica Foundation For Chemop | Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen |
| US20030219846A1 (en) * | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
| US6747025B1 (en) * | 2002-11-27 | 2004-06-08 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
| TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
-
2004
- 2004-12-17 MX MXPA06006862A patent/MXPA06006862A/es not_active Application Discontinuation
- 2004-12-17 US US11/016,116 patent/US20050137147A1/en not_active Abandoned
- 2004-12-17 AU AU2004308911A patent/AU2004308911B2/en not_active Ceased
- 2004-12-17 CA CA002548146A patent/CA2548146A1/en not_active Abandoned
- 2004-12-17 JP JP2006545506A patent/JP2007515422A/ja active Pending
- 2004-12-17 EP EP04814710A patent/EP1696926A1/en not_active Ceased
- 2004-12-17 WO PCT/US2004/042562 patent/WO2005063249A1/en not_active Ceased
- 2004-12-17 ZA ZA200605378A patent/ZA200605378B/xx unknown
- 2004-12-17 BR BRPI0417996-0A patent/BRPI0417996A/pt not_active IP Right Cessation
-
2010
- 2010-03-02 US US12/715,853 patent/US20100204244A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baluchnejadmojarad et al. | Chronic epigallocatechin-3-gallate ameliorates learning and memory deficits in diabetic rats via modulation of nitric oxide and oxidative stress | |
| JP2007515423A5 (enExample) | ||
| Yerra et al. | Isoliquiritigenin reduces oxidative damage and alleviates mitochondrial impairment by SIRT1 activation in experimental diabetic neuropathy | |
| Baluchnejadmojarad et al. | S-allyl cysteine ameliorates cognitive deficits in streptozotocin-diabetic rats via suppression of oxidative stress, inflammation, and acetylcholinesterase | |
| Bhattacharya et al. | Anti‐stress activity of sitoindosides VII and VIII, new acylsterylglucosides from Withania somnifera | |
| Li et al. | Oral dimethyl fumarate reduces peripheral neuropathic pain in rodents via NFE2L2 antioxidant signaling | |
| Zhu et al. | Green tea polyphenols produce antidepressant-like effects in adult mice | |
| JP2007515422A5 (enExample) | ||
| Rajasekar et al. | Intranasal insulin improves cerebral blood flow, Nrf-2 expression and BDNF in STZ (ICV)-induced memory impaired rats | |
| Sharma et al. | Drugs of abuse-induced hyperthermia, blood-brain barrier dysfunction and neurotoxicity: neuroprotective effects of a new antioxidant compound H-290/51 | |
| Wolf et al. | Amphetamine‐induced glutamate efflux in the rat ventral tegmental area is prevented by MK‐801, SCH 23390, and ibotenic acid lesions of the prefrontal cortex | |
| El-Bassossy et al. | Chrysin and luteolin alleviate vascular complications associated with insulin resistance mainly through PPAR-γ activation | |
| Singh et al. | Verapamil augments the neuroprotectant action of berberine in rat model of transient global cerebral ischemia | |
| CA2443229A1 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv | |
| Tschiffely et al. | A comparative evaluation of treatments with 17β-estradiol and its brain-selective prodrug in a double-transgenic mouse model of Alzheimer's disease | |
| CN107441104B (zh) | 人参二醇皂苷Rb组分防治糖尿病并发症及代谢紊乱相关疾病的医药用途 | |
| KR20120058457A (ko) | 근육감소증의 예방 및 치료 | |
| US20130045988A1 (en) | Combination therapy | |
| Cui et al. | Syringin may exert sleep‐potentiating effects through the NOS/NO pathway | |
| Pimple et al. | Ulcer healing properties of different extracts of Origanum majorana in streptozotocin-nicotinamide induced diabetic rats | |
| Kirkland et al. | Delayed recovery and exaggerated infarct size by post-lesion stress in a rat model of focal cerebral stroke | |
| Candelario-Jalil et al. | Neuroprotective efficacy of nimesulide against hippocampal neuronal damage following transient forebrain ischemia | |
| Chipana et al. | Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents | |
| Chang et al. | Alpha-lipoic acid attenuates silica-induced pulmonary fibrosis by improving mitochondrial function via AMPK/PGC1α pathway activation in C57BL/6J mice | |
| CN111727040A (zh) | 用于改善认知能力或认知功能的尿石素a和b的协同组合 |